| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3293191 | Gastroenterology | 2014 | 18 Pages |
Abstract
Based on a case series analysis, concomitant use of nsNSAIDs, COX-2 inhibitors, or low-dose aspirin with SSRIs significantly increases the risk of UGIB. Concomitant use of nsNSAIDs or low-dose aspirin, but not COX-2 inhibitors, with corticosteroids, aldosterone antagonists, or anticoagulants produces significant excess risk of UGIB.
Keywords
GPAIPCIUGIBATCSCCsIRRHSDPPVNSAIDSide effectspositive predictive valueCOX-2 inhibitorParElectronic Health RecordRelative Excess Risk due to InteractionUpper gastrointestinal bleedingnonsteroidal anti-inflammatory drugTreatmentICDRERIPopulation attributable riskSelf-controlled case seriessynergy indexAnatomical Therapeutic ChemicalInternational Classification of Diseasesconfidence intervalStomachSelective serotonin reuptake inhibitorSSRIincidence rate ratioprostaglandinEHR
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Gwen M.C. Masclee, Vera E. Valkhoff, Preciosa M. Coloma, Maria de Ridder, Silvana Romio, Martijn J. Schuemie, Ron Herings, Rosa Gini, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Ernst J. Kuipers, Johan van der Lei,